Bayer chlorinated radon (223Ra) injections in China have been approved for the treatment of prostate cancer.

Dofigo® is a radiation-active therapeutic drug that emits alpha particles, the active part of which simulates calcium ions and is pro-bone by forming a complex with hydroxyphosphate (HAP) in the bone, especially in areas where bone metastasis pathogenic bone hyperpluration is active.
particles emitted by radon-223 can cause high-frequency double-stranded DNA fractures in adjacent tumor cells, resulting in a powerful cytotoxic effect.
, the alpha particle emission radius is less than 100 microns (less than 10 cell diameters) to minimize damage to the surrounding normal tissue.
approval of the ® is based on data from key Phase III ALSYMPCA studies and Phase III studies conducted in Asia 15397.
the study, Dofigo® significantly improved total lifetime (OS) compared to placebo, while delaying the on-the-first symptomatic bone event (SSE).
the risk of adverse events in the treatment group was similar to or even lower in the placebo group, suggesting that ® had good safety.
, the quality of life (QoL) of patients in the treatment group was significantly improved.
source: Bayer.